VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM

Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA discusses the results of a relapsed/refractory multiple myeloma (MM) trial (NCT03145181) of teclistamab, a bispecific BCMA-CD3 antibody that activates T-cell killing of BCMA-expressing MM cells. Subcutaneous (SC) and intravenous administration was investigated in the process of establishing a recommended Phase II dose. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter